tiprankstipranks
Advertisement
Advertisement

PCMVENT Stock Latest News

M Ventures Highlights Academic Spinout Pipeline Through Spinoff Prize 2027
Private CompaniesM Ventures Highlights Academic Spinout Pipeline Through Spinoff Prize 2027
53m ago
MVENT
M Ventures Backs $40 Million Series A Financing for Quintessent AI Photonics Platform
PremiumPrivate Companies
M Ventures Backs $40 Million Series A Financing for Quintessent AI Photonics Platform
15d ago
MVENT
M Ventures Co-Leads €36 Million Series A Financing for Hybrid Drug Developer Remepy
PremiumPrivate Companies
M Ventures Co-Leads €36 Million Series A Financing for Hybrid Drug Developer Remepy
27d ago
MVENT
M Ventures Co-Leads €33 Million Series C Financing for Cyllene Therapeutics
PremiumPrivate Companies
M Ventures Co-Leads €33 Million Series C Financing for Cyllene Therapeutics
2M ago
MVENT
M Ventures Emphasizes Role in U.K. Biotech and Golden Triangle Ecosystem
PremiumPrivate Companies
M Ventures Emphasizes Role in U.K. Biotech and Golden Triangle Ecosystem
2M ago
MVENT
M Ventures Portfolio Advances With FDA Fast Track Wins, Clinical Progress, and Major Licensing Deal
PremiumPrivate CompaniesM Ventures Portfolio Advances With FDA Fast Track Wins, Clinical Progress, and Major Licensing Deal
3M ago
MVENT
M Ventures Highlights FDA Fast Track Milestone for Portfolio Company Nouscom
Premium
Private Companies
M Ventures Highlights FDA Fast Track Milestone for Portfolio Company Nouscom
3M ago
MVENT
M Ventures – Weekly Recap
Premium
Private Companies
M Ventures – Weekly Recap
3M ago
MVENT
M Ventures Portfolio Company Advances Mid-Stage Trial for Novel Breast Cancer Therapy
PremiumPrivate Companies
M Ventures Portfolio Company Advances Mid-Stage Trial for Novel Breast Cancer Therapy
3M ago
MVENT
Early Phase Data for STORM Therapeutics’ METTL3 Inhibitor Signals Potential in Sarcoma
PremiumPrivate Companies
Early Phase Data for STORM Therapeutics’ METTL3 Inhibitor Signals Potential in Sarcoma
4M ago
MVENT
Early-Stage Sarcoma Data Highlight Potential of STORM Therapeutics’ METTL3 Inhibitor
PremiumPrivate Companies
Early-Stage Sarcoma Data Highlight Potential of STORM Therapeutics’ METTL3 Inhibitor
4M ago
MVENT
M Ventures – Weekly Recap
PremiumPrivate Companies
M Ventures – Weekly Recap
4M ago
MVENT
Boehringer Ingelheim Licenses Immunitas Antibody Program in Deal Worth Up to €407.5 Million
PremiumPrivate CompaniesBoehringer Ingelheim Licenses Immunitas Antibody Program in Deal Worth Up to €407.5 Million
4M ago
MVENT
Digital NeuroMarker Focus Puts Altoida in Spotlight Within M Ventures Healthtech Portfolio
Premium
Private Companies
Digital NeuroMarker Focus Puts Altoida in Spotlight Within M Ventures Healthtech Portfolio
4M ago
MVENT
Boehringer Ingelheim Licenses Immunitas Antibody Program in €407.5 Million Deal
Premium
Private Companies
Boehringer Ingelheim Licenses Immunitas Antibody Program in €407.5 Million Deal
4M ago
MVENT
M Ventures – Weekly Recap
PremiumPrivate Companies
M Ventures – Weekly Recap
4M ago
MVENT
Theolytics Advances THEO-260 Into U.S. Phase 1 Trial for Resistant Ovarian Cancer
PremiumPrivate Companies
Theolytics Advances THEO-260 Into U.S. Phase 1 Trial for Resistant Ovarian Cancer
4M ago
MVENT
Theolytics Advances THEO-260 Into Second Clinical Trial for Platinum-Resistant Ovarian Cancer
PremiumPrivate Companies
Theolytics Advances THEO-260 Into Second Clinical Trial for Platinum-Resistant Ovarian Cancer
4M ago
MVENT
M Ventures – Weekly Recap
PremiumPrivate Companies
M Ventures – Weekly Recap
5M ago
MVENT
Lightcast Secures $27 Million Financing to Advance Envisia Single-Cell Platform
PremiumPrivate CompaniesLightcast Secures $27 Million Financing to Advance Envisia Single-Cell Platform
5M ago
MVENT
Lightcast Financing Round Signals Expansion Potential for M Ventures’ Portfolio
Premium
Private Companies
Lightcast Financing Round Signals Expansion Potential for M Ventures’ Portfolio
5M ago
MVENT
STORM Therapeutics Raises $56 Million Series C to Advance METTL3 Inhibitor Program
Premium
Private Companies
STORM Therapeutics Raises $56 Million Series C to Advance METTL3 Inhibitor Program
5M ago
MVENT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >